HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Industry Roundup: SEC Fines MJN, Criminal Charge For Herbals Seller, Decree Closes Aspen Supplement Marketer

This article was originally published in The Tan Sheet

Executive Summary

FCPA violations cost Mead Johnson $12M; decree closes Aspen supplement marketer; equity funding for SmartyPants; homeopathic online retailer warned; ForeverGreen launches strong; and more news in brief.

You may also be interested in...



QHC study

FDA plans to conduct a study to "further explore" the use of report card grading schemes in qualified health claims (QHCs), according to a notice published in the Federal Register May 22. The study builds off previous research that found report card schemes were effective in conveying the "intended ordering of scientific certainty," but led consumers to be more certain of "B" and "C" claims than claims of higher scientific certainty, which did not receive a grade (1"The Tan Sheet" Oct. 10, 2005, p. 7). The proposed study will attempt to correct for "misperceptions" observed in the previous study and will position unqualified claims as "A" grade claims. Additionally, the study will use actual health claims and variants of these claims rather than hypothetical claims. Green tea and cancer, coronary heart disease and consumption of monounsaturated fatty acids from olive oil as well as omega-3 fatty acids and CHD claims will be used. An earlier version of the study was proposed in March 2005 (2"The Tan Sheet" April 4, 2005, In Brief)...

Indoco Builds On Recent Growth With Acquisition In US

Indoco says it has marked a major milestone with a $4m deal to take a controlling stake in US firm Florida Pharmaceutical Products, strengthening the Indian company’s position in the US market.

ChatGPT Unleashed: Generative AI Use Cases Taking Off In Pharma

As generative AI and its star avatar, ChatGPT, take the world by storm, pharma is seeing traction for use cases around smarter pharmacovigilance and commercial marketing content development, among others. Senior executives from Indegene discuss this and more in an interview with Scrip.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS123461

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel